Anifrolumab brand name. Type 1 interferons (INF) are proteins that help your body fight viruses. [medical citation needed] Oct 10, 2024 · Anifrolumab infusion is used for moderate to severe systemic lupus erythematosus (SLE) in adults who are also receiving other lupus medicines. . SAPHNELO® (anifrolumab-fnia) infusion is a treatment for adults with moderate to severe systemic lupus erythematosus who are receiving standard lupus medications. 1 The safety profile observed in the Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. Anifrolumab works to reduce the body's immune and inflammatory response, which helps improve symptoms of SLE. Anifrolumab is a medicine used as an add-on treatment for adult with moderate to severe systemic lupus erythematosus (SLE), a disease in which the immune system attacks the body causing inflammation and organ damage. Sep 17, 2025 · Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca’s Saphnelo (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo. ANIFROLUMAB (an i frol ue mab) treats certain types of lupus. Dec 18, 2019 · We report the findings of TULIP-2, a second phase 3 trial of anifrolumab in active SLE using the BICLA secondary end point from the first phase 3 trial as its primary end point. It is used to treat systemic lupus erythematosus (SLE). Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. Feb 1, 2025 · Anifrolumab-fnia injection is used to treat moderate to severe systemic lupus erythematosus (SLE) in patients who are also receiving other lupus treatments. Medscape - Systemic lupus erythematosus dosing for Saphnelo, anifrolumab-fnia (anifrolumab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & What is Anifrolumab? Anifrolumab is a type of medicine called a biological disease-modifying antirheumatic drug (bDMARD). Chronic activation of the type I interferon (IFN) pathway plays a critical role in systemic lupus erythematosus (SLE) pathogenesis. It is a monoclonal antibody that changes the immune system to help control lupus symptoms. It works by slowing down an overactive immune system, which reduces inflammation and other symptoms of lupus. Anifrolumab is a human monoclonal antibody to the type I IFN receptor subunit 1, which blocks the action of type I IFNs. [5][7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. Anifrolumab-fnia is a type I interferon (IFN) receptor antagonist, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that is produced in mouse myeloma cells (NS0) by recombinant DNA technology. aronhc jk9 gsp mrjxths pmasa oyqo tqu gm jwla3 ayeu93